检索结果-南通市图书馆

仅有肝棘球蚴病临床表现的过敏性休克患者1例报道

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（皮肤病学分册） 2005年第7期1卷 55-55页

作者： georgiou S. Maroulis J. Monastirli A. 牛新武 Department of Dermatology School of Medicine University of Patras PO Box 1413 Rio-Patras 26500 Greece Dr.

The case of a 35-year-old man is reported who developed a spontaneous anaphylactic shock as the only clinical manifestation of hepatic hydatidosis. Dermatologists should consider asymptomatic hydatid disease in the differential diagnosis of anaphylactic reactions, particularly in patients from regions in which echinococcosis is endemic.

关键词：过敏性休克肝棘球蚴病皮肤科医生无症状

维普期刊数据库

抵抗素基因启动子的多态性与多囊卵巢综合征妇女的体重指数相关

在线全文

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（妇产科学分册） 2005年第4期1卷 51-51页

作者： Xita N. georgiou I. Tsatsoulis A. 朱国栋

Resistin does not appear to be a major gene predisposing to polycystic ovary syndrome (PCOS). However, an association of a resistin variant with body mass index was found in women with PCOS, suggesting that resistin m... 详细信息

关键词：多囊卵巢综合征抵抗素基因指数相关启动子多态性易感基因

维普期刊数据库

具有脑卒中危险因素的无症状人群中潜在脑微血管疾病替代标志

在线全文

学校读者我要写书评

暂无评论

国际医学放射学杂志 2009年第3期 311-311页

作者： J.Selvarajah M.Scott S.Stivaros S.Hulme R.georgiou N.Rothwell 杨卉 Imaging Science and Biomedical Engineering School of MedicineUniversity of ManchesterManchesterM13 9PTUK

脑微血管病变(MVA)与临床上多种血管危险因素有关,具有组织学特征,包括动脉血管壁增厚,Virchow-Robin间隙(VRS)的扩大。我们曾描述了MVA基于MRI的2种新的生物学标志,即VRS间隙的扩大以及因脑血管壁顺应性下降导致的动脉收缩期搏动异常... 详细信息

脑微血管病变(MVA)与临床上多种血管危险因素有关,具有组织学特征,包括动脉血管壁增厚,Virchow-Robin间隙(VRS)的扩大。我们曾描述了MVA基于MRI的2种新的生物学标志,即VRS间隙的扩大以及因脑血管壁顺应性下降导致的动脉收缩期搏动异常传导至脑室内脑脊液。这些与血管性痴呆及难治性迟发性抑郁症(treatment-resistant lateonset depression)有关。

关键词： MRI 微血管病变卒中风险

白介素-1受体拮抗剂治疗急性卒中患者的随机Ⅱ期研究

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

世界核心医学期刊文摘(神经病学分册) 2006年第1期 25-25页

作者： Emsley H.C.A. Smith C.J. georgiou R.F. N.J. Rothwell 方伯言 Faculty of Life Sciences University of Manchester Michael Smith Building Oxford Road Manchester MI 3 9PT United Kingdom Prof.

Objectives: The cytokine interleukin (IL)-1 mediates ischaemic brain damage in rodents. The endogenous, highly selective, IL-1 receptor antagonist (IL-1ra) protects against ischaemic cerebral injury in a range of experimental settings, and IL-1ra causes a marked reduction of cell death when administered peripherally or at a delay in transient cerebral ischaemia. We report here the first randomised, double blind, placebo controlled trial of recombinant human IL-1ra (rhIL-1ra) in patients with acute stroke. Methods: Patients within 6 hours of the onset of symptoms of acute stroke were randomised to rhIL-1ra or matching placebo. Test treatment was administered intravenously by a 100 mg loading dose over 60 seconds, followed by a 2 mg/kg/h infusion over 72 h. Adverse events and serious adverse events were recorded for up to 3 months, serial blood samples were collected for biological markers up to 3 months, and 5-7 day brain infarct volume was measured by computed tomography. Results: No adverse events were attributed to study treatment among 34 patients randomised. Markers of biological activity, including neutrophil and total white cell counts, C reactive protein, and IL-6 concentrations, were lower in rhIL-1ra treated patients. Among patients with cortical infarcts, clinical outcomes at 3 months in the rhIL-1ra treated group were better than in placebo treated. Conclusions: These data suggest that rhIL-1ra is safe and well tolerated in acute stroke. In addition, rhIL-1ra exhibited biological activity that is relevant to the pathophysiology and clinical outcome of ischaemic stroke. Our findings identify rhIL-1ra as a potential new therapeutic agent for acute stroke.

关键词：急性卒中白介素患者受体拮抗剂